Literature DB >> 9625326

Pharmacological treatment of portal hypertension: present and future.

D Lebrec1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625326     DOI: 10.1016/s0168-8278(98)80241-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  7 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

Authors:  J Vlachogiannakos; A K Tang; D Patch; A K Burroughs
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

Review 2.  Drug therapy for portal hypertension.

Authors:  D Lebrec
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

3.  Variceal Bleeding.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

4.  NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.

Authors:  S Fiorucci; E Antonelli; O Morelli; A Mencarelli; A Casini; T Mello; B Palazzetti; D Tallet; P del Soldato; A Morelli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

Review 5.  Management of acute variceal bleeding.

Authors:  Young Dae Kim
Journal:  Clin Endosc       Date:  2014-07-28

6.  Percentage of peak-to-peak pulsatility of portal blood flow can predict right-sided congestive heart failure.

Authors:  Jui-Ting Hu; Sien-Sing Yang; Yun-Chih Lai; Cheng-Yen Shih; Cheng-Wen Chang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

7.  Proinflammatory liver and antiinflammatory intestinal mediators involved in portal hypertensive rats.

Authors:  Maria Angeles Aller; Elena Vara; Cruz Garcia; Maria Dolores Palma; Jorge L Arias; Maria Paz Nava; Jaime Arias
Journal:  Mediators Inflamm       Date:  2005-06-09       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.